Welfare Genome Project: A Participatory Korean Personal Genome Project With Free Health Check-Up and Genetic Report Followed by Counseling by Jeon, Yeonsu et al.
fgene-12-633731 February 3, 2021 Time: 14:52 # 1
PERSPECTIVE




Kwansei Gakuin University, Japan
Reviewed by:
Juliana F. Mazzeu,
University of Brasilia, Brazil
Giovanna Elisa Calabrò,







†These authors have contributed
equally to this work
Specialty section:
This article was submitted to
ELSI in Science and Genetics,
a section of the journal
Frontiers in Genetics
Received: 27 November 2020
Accepted: 20 January 2021
Published: 09 February 2021
Citation:
Jeon Y, Jeon S, Blazyte A,
Kim YJ, Lee JJ, Bhak Y, Cho YS,
Park Y, Noh EK, Manica A,
Edwards JS, Bolser D, Kim S, Lee Y,
Yoon C, Lee S, Kim BC, Park NH and
Bhak J (2021) Welfare Genome
Project: A Participatory Korean
Personal Genome Project With Free




Welfare Genome Project: A
Participatory Korean Personal
Genome Project With Free Health
Check-Up and Genetic Report
Followed by Counseling
Yeonsu Jeon1,2†, Sungwon Jeon1,2†, Asta Blazyte1,2†, Yeo Jin Kim3, Jasmin Junseo Lee1,4,
Youngjune Bhak1,2, Yun Sung Cho3, Yeshin Park3,5, Eui-Kyu Noh6, Andrea Manica7,
Jeremy S. Edwards8, Dan Bolser9, Sukyeon Kim1, Yuji Lee1, Changhan Yoon1,2,
Semin Lee1,2, Byung Chul Kim3, Neung Hwa Park10* and Jong Bhak1,2,3,11*
1 Korean Genomics Center (KOGIC), Ulsan National Institute of Science and Technology (UNIST), Ulsan, South Korea,
2 Department of Biomedical Engineering, College of Information-Bio Convergence Engineering, Ulsan National Institute
of Science and Technology (UNIST), Ulsan, South Korea, 3 Clinomics Inc., Ulsan, South Korea, 4 Human Biology Program,
Faculty of Arts and Sciences, University of Toronto, Toronto, ON, Canada, 5 Department of Medical Sciences, Graduate
School of Ajou University School, Suwon, South Korea, 6 Department of Hematology and Oncology, Ulsan University
Hospital, University of Ulsan College of Medicine, Ulsan, South Korea, 7 Department of Zoology, University of Cambridge,
Cambridge, United Kingdom, 8 Department of Chemistry and Chemical Biology, University of New Mexico Comprehensive
Cancer Center, University of New Mexico, Albuquerque, NM, United States, 9 Geromics Ltd., Cambridge, United Kingdom,
10 Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, South Korea,
11 Personal Genomics Institute (PGI), Genome Research Foundation (GRF), Osong, South Korea
The Welfare Genome Project (WGP) provided 1,000 healthy Korean volunteers with
detailed genetic and health reports to test the social perception of integrating personal
genetic and healthcare data at a large-scale. WGP was launched in 2016 in the Ulsan
Metropolitan City as the first large-scale genome project with public participation in
Korea. The project produced a set of genetic materials, genotype information, clinical
data, and lifestyle survey answers from participants aged 20–96. As compensation, the
participants received a free general health check-up on 110 clinical traits, accompanied
by a genetic report of their genotypes followed by genetic counseling. In a follow-
up survey, 91.0% of the participants indicated that their genetic reports motivated
them to improve their health. Overall, WGP expanded not only the general awareness
of genomics, DNA sequencing technologies, bioinformatics, and bioethics regulations
among all the parties involved, but also the general public’s understanding of how
genome projects can indirectly benefit their health and lifestyle management. WGP
established a data construction framework for not only scientific research but also the
welfare of participants. In the future, the WGP framework can help lay the groundwork
for a new personalized healthcare system that is seamlessly integrated with existing
public medical infrastructure.
Keywords: genomics, personal genome project, Korean genome project, population study, integrated healthcare,
genetic report
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INTRODUCTION
Next-generation sequencing technologies have promoted a
variety of personal genome projects (Ball et al., 2012, 2014;
Oleksyk et al., 2015; Walter et al., 2015; Cho et al., 2016) aiming to
map and analyze whole genome information concerning personal
characteristics, population structure, disease risk, and even
ancestry prediction (Supplementary Table 1). To this date there
are more than three dozens of national-ethnic genome projects
worldwide, sequencing human genomes or exomes with diverse
goals in various stages of implementation; a number of countries
such as the United Kingdom, China, and South Korea have
carried out multiple such initiatives (Supplementary Table 1).
The Personal Genome Project (PGP) from Harvard Medical
School led by George Church (Church, 2005) laid the foundation
for all of these independent projects by promoting a voluntary
individual driven data collection and sharing by the general
public. In a way, it reflects the universal trend of democratizing
many aspects of human society and tries to provide personal
health benefits based on each person’s sovereignty over his or her
own genomic and clinical data. Currently, however, most genome
projects are top-down and driven by government initiatives. The
first such government-led project to address genomic diversity
on a population scale was UK10K launched in 2010 (Walter
et al., 2015). It was a British government-funded collaboration
with existing projects [TwinsUK (Moayyeri et al., 2013) and
ALSPAC (Boyd et al., 2013) cohorts]. UK10K almost entirely
focused on diseases such as autism, schizophrenia, and rare
conditions. Many subsequent government projects all across the
world took similar trajectories: the 100,000 Genomes Project1
by Genomics England focused on patients with cancer and
rare diseases, Genome Canada2 collected 10,000 rare disease
trios, and the Ashkenazi Genome Consortium gathered most of
their samples from schizophrenia patients (Lencz et al., 2018).
More recently, the United Kingdom’s 100,000 Genomes Project
approach was adapted by the Taiwanese G2020 Population
Genomics Pilot project3 aiming at 10,000 participants, while in
China several complex disease cohorts were combined for a
large-scale ChinaMAP project (Cao et al., 2020).
In addition to disease-related large-scale genome projects,
population structure studies have also been initiated as a popular
tool to understand the history of human migration and gene
flow. Many projects have emerged worldwide for this purpose,
acquiring their samples through general population recruitment
(Gudbjartsson et al., 2015; Leitsalu et al., 2015; Nagasaki et al.,
2015; Ameur et al., 2017; Jeon et al., 2020; Supplementary
Table 1). The practical goal and outcome of such non-disease
genome projects are to collect and bank as much genomic
data as possible for subsequent uses, such as the study of fine
stratification of populations. While all these public projects are
designed to eventually help the participants and researchers, they





Group in 2015 (Hudson et al., 2015), unidirectional in terms of
benefits and data sharing from the participants’ point of view.
Recently, however, large-scale projects such as “All of Us”4 and
the “100,000 Genomes Project” (see text footnote 1) released
the data generated during the study back to the participants or
offered the participants some kind of welfare benefit, including
disease diagnosis (Supplementary Table 1). Here, we present
the Welfare Genome Project (WGP) funded by the Korean
government and the cities of Ulsan and Miryang. It was launched
in 2016 in two adjacent cities, Ulsan and Miryang. From the start,
WGP had the purpose of providing benefits to the participants.
Since all participants are fairly homogeneous in terms of ethnicity
and free from serious diseases, their genomic and clinical data
can be used as the first standard dataset for a healthy Korean
population (∼51 million people5).
Ulsan is a metropolitan city in the southeast of Korea with
a population of 1.1 million6. Excluding Seoul, the capital, six
major cities hold a special “metropolitan” status based on
comprehensive consideration of their population size, land area,
location, and socioeconomic status (Korea Mois, 2020). The
industrialization of Korea attracted people from all over the
nation to work in numerous factories and global corporations
located in Ulsan, such as the Hyundai group. Adjacent to Ulsan
is Miryang, a landlocked agricultural city with a population of
approximately 100,000 (see text footnote 6). In Korea, conducting
genomic sequencing commercially or privately to provide genetic
reports is restricted under the regulation of the Bioethics and
Safety Act. However, providing such reports to the scientific
research participants is allowed if the participants express their
interest in receiving the genetic reports. Therefore, WGP is also
a social experiment acquiring preliminary insight on whether
providing genetic reports can be beneficial to the general public in
a particular legal and cultural system. WGP aims to disseminate
technical information such as why a welfare-oriented genome
project was initiated, what procedures were developed under
Korea’s healthcare environment, and how participants were
rewarded for their participation.
WELFARE GENOME PROJECT
STRUCTURE
Welfare Genome Project is the first research-based participatory
personal genome project in Korea. The project collected and
banked genomic, clinical, and lifestyle data from 1,000 healthy
volunteers and provided them with a combined genetic and
health information service. The genome project was designed
to find ways to maximize health and welfare benefits to citizens
of participating cities. It was designed, managed, and carried
out by the Korean Genomics Center (KOGIC) at the Ulsan
National Institute of Science and Technology (UNIST) and
the Ulsan University Hospital (UUH) supported by the cities
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FIGURE 1 | Gender and Age distribution in the Welfare Genome Project. The
map shows regions sampled in South Korea. 80% of the participants were
from Ulsan, while the remaining 20% were from Miryang. The numbers in the
figure show the distribution by gender and age in the Welfare Genome Project.
and sample banking were handled by UUH. The generation of
personal genetic reports (PGR), screening for common disease
risks, physical characteristics, drug responses, and rare disease-
associated variants, were carried out by external genomics
companies (Supplementary Tables 2–5). WGP was not a cohort
study and the participants were not asked to consent to be
contacted again for further research at the time of enrollment.
Even though all participants were healthy at the time of
enrollment, they received an extensive free health check-up
at UUH. WGP’s recruitment was carried out by mass media
advertisements such as TV commercials and banners in public
gathering places, with support from local governments in Ulsan
and Miryang. The overall response from the media, cities, and
citizens was quite favorable.
WELFARE GENOME PROJECT
PROCEDURE
The application procedure was carried out online7. Since there
was a capacity of 1,000 participants, volunteers from Ulsan and
Miryang were selected by a competitive rate of 4.9:1. After
classification into respective gender and age groups, participants
were randomly selected from their groups to allocate and
distribute them as evenly as possible (Figure 1). All participants
signed an informed consent form and agreed to; (i) provide
blood-derived materials such as DNA and RNA, (ii) make clinical
information derived from their health check-up available, and
(iii) answer a lifestyle questionnaire (Figure 2). The information
provided was banked in the Ulsan University Hospital Biobank.
The participants then underwent an extensive health check-up
7http://ulsan1000.genomekorea.kr/
covering 110 clinical traits (Supplementary Table 6), answered a
lifestyle-based questionnaire with 137 questions (Supplementary
Table 7), and donated 35 ml of blood. The entire process was
completed in one visit to UUH (Figure 2).
Approximately 30 days after the initial visit to UUH,
the participants were informed of the completion of their
PGR, and the participants were required to schedule the
final hospital visit for the dissemination of PGR and health
check-up results. Doctors provided the participants with their
genotype information and explained disease risk scores that are
relevant to healthcare and lifestyle, ensuring that the participants
received information from medical experts, avoiding possible
misinterpretation of the results. On average, it took 45 days from
the blood donation to the final consultation, depending on the
participant’s availability.
The blood-derived materials, clinical information, lifestyle
questionnaire answers, and data generated from them, were
transferred to the UUH Biobank. The blood-derived materials
were separated into derivatives such as plasma and serum,
then anonymized by barcodes using an anonymization program
provided by the Korea Centers for Disease Control and
Prevention (KCDC) to prevent personal identification by
researchers. The blood-derived materials were banked after being
stored in a liquid nitrogen tank and deep freezer in the UUH
Biobank. The participants’ genotype data were banked together
with DNA and RNA at the UUH Biobank.
BENEFITS FOR PARTICIPANTS:
PERSONAL GENETIC REPORT
The number of traits examined through PGR for the participants
differed by year (Supplementary Table 2). The one in 2016
covered 46 common disease risks, five physical characteristics,
five drug responses, and 44 rare diseases (Supplementary
Figure 1 and Supplementary Tables 2, 3). The PGR in 2017
contained 50 common disease risks, eleven drug responses,
27 personal characteristics (such as vitamin and caffeine
metabolism), and 24 hereditary diseases (Supplementary
Tables 2, 4). In 2018, it contained 38 common disease risks, five
physical characteristics, five drug responses, and 44 rare diseases
(Supplementary Tables 2, 5).
The prevalence of the disease, as well as the participant’s
relative risk, was also provided for reference. The participant’s
relative risks in the report were subdivided into three to
four different risk levels. The risk levels were defined by
pathogenicity of genotypes. In 2016 and 2018 there were
four levels (management required, elevated, moderate, or mild)
(Supplementary Figure 1), but in 2017 the report was simplified
to have three risk levels (intensive management required,
attention required, and general management). However, critical
traits, including the responses to drugs such as warfarin or
anticancer drugs and predisposition to myocardial infarction,
obesity, arthritis (osteoarthritis and rheumatoid arthritis), atopic
dermatitis, alcohol dependence and type 2 diabetes as well as
myopia-risk, were consistently covered by all the PGR versions.
Furthermore, we screened for and provided the participants with
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FIGURE 2 | The procedure of Welfare Genome Project. (A) Recruitment of participants. (B) Sample collection (Blood/Data donation) (C) Sample and data banking to
Ulsan University Hospital Biobank. (D) Providing genetic and health check reports with clinical counseling.
the genotypes of certain disease-related genes, such as APOB
for familial hypercholesterolemia type B and AGL for glycogen
storage type III, CFTR for cystic fibrosis, and VWF for Von
Willebrand disease each year.
BENEFITS FOR PARTICIPANTS: HEALTH
CHECK-UP AND REPORT
The participants received an extensive free health check-up.
A health report was provided to the participants, which evaluated
110 clinical traits (79 of which were quantitative) and included
results from eleven physical traits (i.e., obesity and blood
pressure), as well as hematological quantitative results from 16
categories (i.e., blood sugar and thyroid hormones levels). In
comparison, the National Health Insurance Corporation (NHIS)
health check-up of Korea screens for 17 categories8, several of
which are fundamental to one’s health status and are also present
in the WGP health check-up. However, while WGP assessed
every patient for all of the categories regardless of their physical
characteristics, NHIS has eight items that are sex and age-specific.
For instance, WGP tested every patient for hepatitis B, while
NHIS only tests those who are 40 and younger as they are
considered to be at a higher risk.
8https://hi.nhis.or.kr/aa/ggpaa001/ggpaa001_m01.do
PARTICIPANTS’ RESPONSE TO THE
SURVEY
After the completion of the project, participants were surveyed
on their participation experience (Supplementary Figure 2).
Most participants (96.1%) recognized the necessity of WGP
(Supplementary Figure 2A) and 87.9% were aware of how
genetics affects disease outcomes (Supplementary Figure 2B).
Around 92.6% of the participants were satisfied with checking
their health (Supplementary Figure 2C) and nearly the
same number of participants (92.5%) thought their health
information was delivered well (47.8%) or very well (44.7%)
(Supplementary Figure 2D). Unsurprisingly, participants were
interested to apply genetic information to understand their
health since 63.1% of the respondents found PGR to be
the most satisfying part of the participation (Supplementary
Figure 2E). Moreover, the majority of participants were
positive or enthusiastic about donating their blood samples
(93.3%) (Supplementary Figure 2F) and clinical data (92.6%)
(Supplementary Figure 2G). Approximately 94.7% of the
participants answered that knowing their genetic information
can positively impact their life (Supplementary Figure 2H),
and 91.0% responded that this project encouraged them to
consider making lifestyle changes toward health improvement
(Supplementary Figure 2I). Overall, the majority of the Ulsan
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and Miryang citizens were satisfied with the participation
experience and services provided.
EXTENSION OF THE WELFARE GENOME
PROJECT
The samples banked to the Biobank of Ulsan University Hospital
already proved to be a valuable resource to the scientific
community, as they have been used in Korea1K, the biggest
South Korean population genome project. Jeon et al. (2020)
sequenced the whole genome of 696 out of 1,000 samples banked
by WGP and used the 79 quantitative clinical traits to investigate
genome-wide associations between the variants and the clinical
information. Another application demonstrated by the study
was the development of a Korean panel of normals for cancer
genomics researches, which is an invaluable resource when a
matched healthy control from the same individual is not available
(e.g., leukemia).
Furthermore, one of the most impactful applications of such
a large-scale WGS is building a genotype imputation panel. Since
an imputation panel can be used to impute unknown genotypes,
this can be a useful resource for many genome-wide association
studies and clinical studies. The Korea1K genotype imputation
panel, which includes a large number of samples from the same
population (Koreans), also showed a strong increase in predictive
power (Jeon et al., 2020).
Due to a relatively even age stratification among the
samples and both DNA and RNA availability, WGP samples
can also be used for aging research via gene expression and
methylation profiling. Other potential applications can utilize the
banked clinical information and lifestyle survey results focusing
on genotype effect on simple (e.g., lactose intolerance) and
complex phenotypes (e.g., obesity, susceptibility to cancers). The
genomic data generated is a useful resource for interpopulation
comparisons. Additionally, the large number of genomes can
give enough resolution for population structure estimation. The
publication by Jeon et al. (2020) is just a first example of WGP
samples being successfully used for future research.
DISCUSSION
Despite the support and positive outlook from the general public,
WGP encountered two major limitations. The first shortcoming
was the lack of genetic counselors who could perform a
consultation at the recruiting stage and later interpret and explain
the genetic report results to the participants at the report stage.
While general practitioners can partially fill in the counseling
role, their genetic interpretations may lack depth. This becomes
even of higher importance when we consider the recent estimates
(2006–2020), where the general population recruited to omics
projects in most studies (64%) does not have a sufficient level of
knowledge about genomics (Calabrò et al., 2020). However, the
competence of general practitioners involved in genome projects
has already been demonstrated by Estonian Biobank, another
project recruiting the general population (Leitsalu et al., 2015).
Secondly, genomic data are classified as personal information,
which South Korea strictly regulates via the Bioethics and
Safety Act9. Initially, the Act emphasizes the need for consent
form the individual as a human subject of research. Upon its
donation to a human material biobank, genetic data must be
anonymized to prevent personal identification (Article 44-2)
(see text footnote 9). In the case that a subject’s information
is breached, the Act states that one cannot be discriminated
against based on their genetic information (Article 46-1) (see text
footnote 9). Although such laws serve to ensure ethical use and
protect the security of participants’ genetic data, the ambiguity
in their interpretation creates a non-sensical situation where
subjects may participate in WGP-like projects and receive the
genetic report but are prohibited from receiving their genome
sequence. As in FinnGen (Ritari et al., 2020)10 and All of
United States (see text footnote 4) projects, the WGP genomic
data were planned to be integrated into healthcare systems
(Supplementary Table 1), but it was impossible by the time of
WGP completion. Inspired by this limitation, in 2020, after the
project was completed, Ulsan city government was motivated to
establish a special Genome Regulation Free Zone status from the
government (Ulsan Genome Service Industry Regulation-Free
Special Zone), authorizing the transfer of genome information
to third parties such as public biobanks and biotech companies
as well as returning it to the participants (see text footnote
10). While an exception was made for Ulsan city, current
regulations in Korea are still not favorable for the development
of personalized medicine, capping the scale and usefulness of
projects like WGP.
We showed that both researchers and volunteers can benefit
simultaneously by raising the public interest in WGP, especially
for the participants who received the health check-up and genetic
report, the key factor differentiating WGP from other genome
projects. Ultimately, the omics data set of relatively healthy
people is important and can be used as universal demographic
control data for cancer, rare disease, aging, and population
structure studies. As it is important to monitor the public interest
and provide continuous education and information on genetic
predisposition, we conducted a survey after the project. The
responses to the survey suggest that allowing participation in
genomic research and providing detailed information about their
own genome sequences is an effective way to educate people
about genomics and genetic association with diseases. As an
outcome of the project, we identified some participants becoming
more motivated in taking care of their health than before WGP
participation (Supplementary Figure 2I). Perhaps the most
important social impact we have discovered was that majority
of the participants were quite positive (>90% positive response)
about donating their genomic as well as clinical information,
and understood how their genome could be used as a resource
for healthcare research. The response was consistent with the
survey results by the Korea Centers for Disease Control and
Prevention (KCDC) (Kim et al., 2020) and comparable to the
9https://elaw.klri.re.kr/eng_mobile/viewer.do?hseq=33442&type=part&key=36
10https://www.finngen.fi/en/goals_and_benefits
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results of the 100,000 Genome Project11 and Qatar Genome
Program (QGP) (Qoronfleh et al., 2020). Certainly, it is important
to note that our participants’ response was intrinsically biased
by the free benefits they received. However, WGP’s survey
was only on the participants, while QGP (Qoronfleh et al.,
2020) surveyed the general Qatari population with which 71%
responded positively toward the genome project. Therefore,
the overwhelmingly positive response in our study may be
biased but not unprecedented. On the other hand, the scope
of the United Kingdom’s 100,000 Genome Project complicates
its comparison with WGP. Despite the differences, 73% of the
100,000 Genomes Project participants were positive about their
involvement, which is highly consistent with our survey results,
and 86% would return to future genomic initiatives (see text
footnote 12). Furthermore, one additional aspect of WGP was
that companies participated in producing genetic reports by
acquiring single nucleotide variant (SNV) information. Although
it was limited in terms of traits and the number of SNVs, it was
the first case in Korea where commercial entities provided their
genetic report products to the general public as a part of this
research project.
Additionally, regarding the clear rules for the ethnical
use of data and data ownership, participants were clearly
informed and agreed to the donation of human materials after
accepting the following guideline established by UUH Biobank:
“Participants don’t have rights for product development and
patent applications based on research results using human
materials provided by participants. The research results can be
published in academic conferences and journals in the name of
the research and participant’s personal information will not be
revealed.” However, their close relatives may raise legal issues
on the genetic information that will be publicly shared in the
future although participants have fully agreed to donate their
genomic data for scientific research. This issue may escalate
further when a great number of large-scale genome projects are
launched in the future. The establishment of unified international
standards on consenting and data sharing would partly resolve
the legality regarding the personal and family privacy issue of
genome projects. However, this is an issue beyond the scope
of WGP. Furthermore, as more commercial DNA tests become
available, internal security measures cannot completely prevent
possible unwanted identification through genome information,
since individuals are traceable by genetic similarity. Thus, one
should be mindful when acquiring their genetic information.
The representativeness of samples must also be considered
carefully. WGP sampling was conducted only in two cities, thus
insufficient in representing the genomic diversity of the entire
Korean population. While it is a geographically limited approach,
the industrial and metropolitan aspects of Ulsan suggest that
it attracted people from all over the country, contributing to
its genomic diversity. Furthermore, most population genetics
studies on Koreans so far indicated that Koreans are genetically
homogeneous (Kim et al., 2010; Hong et al., 2014; Cho et al.,
2016; Jeon et al., 2020). Thus, we concluded that the possible
11https://www.geneticalliance.org.uk/wp-content/uploads/2019/07/Patient-
Experience-100000GP.pdf
sampling bias of WGP is not critical. The outcome of this
project demonstrates that Korean citizens are fairly open to
participation in large-scale personal and public genome projects.
If expanded, the WGP model can be applied not only in other
Korean provinces, but in other regions worldwide.
Overall, the genomic and clinical data generated by WGP can
be a very useful future resource. It can serve as a standardized
control set when investigating many diseases. Furthermore,
providing a pilot path for genome projects by reducing
uncertainty in bioethics regulations could potentially advance
the current Korean healthcare system, improving personalized
medicine using genetic predispositions and metabolic traits.
This may ultimately facilitate society to build a personal
healthcare system that is seamlessly integrated with existing
public medical infrastructure. For example, a set of genomic
and clinical information resources would allow integrating
innovative approaches such as polygenic risk score calculation
and prediction, which has been shown to improve risk prediction
accuracy for patients of coronary artery diseases (Elliott et al.,
2020). Therefore, participants may benefit from WGP over their
lifetime by acquiring their genetic information especially when it
is integrated into a preventive healthcare service in the future.
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